Clinical Trial Update: UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing UVA-Riboflavin crosslinking for keratoconus and corneal ectasia; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Ectasia
• Keratoconus

Drugs mentioned

• UVA-Riboflavin Crosslinking (riboflavin crosslinking with UVA irradiation)

Snippet

Sponsor: Mercy Center for Corrective Eye Surgery | Conditions: Keratoconus, Ectasia | Phase 2 | Status: UNKNOWN